Topotecan treatment of adults with primary malignant glioma. The Brain Tumor Center at Duke.


Journal Article

BACKGROUND: Topotecan activity was evaluated for the treatment of malignant glioma. METHODS: Sixty-three patients with newly diagnosed (n = 25) or recurrent (n = 38) malignant glioma were treated with topotecan [AU: Please verify all dosages here and throughout text.]at a dose of 2.6 mg/m2 over a 72-hour period weekly. Recurrent tumors included glioblastoma multiforme (GBM) (n = 28) and anaplastic astrocytoma (AA) (n = 10). Newly diagnosed tumors included GBM (n = 14), AA (n = 8), and anaplastic oligodendroglioma (n = 3). RESULTS: Partial responses were observed in 2 of 14 evaluable patients with newly diagnosed GBM, 1 of 8 patients with newly diagnosed AA, 3 of 10 patients with recurrent AA, and none of 28 patients with recurrent GBM. Four patients with recurrent AA and 7 patients with recurrent GBM demonstrated stable disease (range, 8-52 weeks; median, 21 weeks). Toxicity was limited to infrequent National Cancer Institute Common Toxicity Criteria Grade 3 myelosuppression. CONCLUSIONS: These results suggest that topotecan has modest activity against malignant glioma and continued evaluation of its effectiveness may be warranted when alternative schedules or combination regimens are used.

Full Text

Duke Authors

Cited Authors

  • Friedman, HS; Kerby, T; Fields, S; Zilisch, JE; Graden, D; McLendon, RE; Houghton, PJ; Arbuck, S; Cokgor, I; Friedman, AH

Published Date

  • March 1, 1999

Published In

Volume / Issue

  • 85 / 5

Start / End Page

  • 1160 - 1165

PubMed ID

  • 10091802

Pubmed Central ID

  • 10091802

International Standard Serial Number (ISSN)

  • 0008-543X


  • eng

Conference Location

  • United States